Purple Biotech Ltd (PPBT)
NASDAQ: PPBT · Real-Time Price · USD
0.7655
+0.0035 (0.46%)
At close: Nov 21, 2025, 4:00 PM EST
0.7547
-0.0108 (-1.41%)
Pre-market: Nov 24, 2025, 4:27 AM EST
Purple Biotech Employees
Purple Biotech had 9 employees as of December 31, 2024. The number of employees decreased by 11 or -55.00% compared to the previous year.
Employees
9
Change (1Y)
-11
Growth (1Y)
-55.00%
Revenue / Employee
n/a
Profits / Employee
-$361,222
Market Cap
6.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9 | -11 | -55.00% |
| Dec 31, 2023 | 20 | 0 | - |
| Dec 31, 2022 | 20 | 1 | 5.26% |
| Dec 31, 2021 | 19 | 6 | 46.15% |
| Dec 31, 2020 | 13 | 4 | 44.44% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PPBT News
- 9 days ago - Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 26 days ago - Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform - GlobeNewsWire
- 4 weeks ago - Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification - GlobeNewsWire
- 2 months ago - Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants - GlobeNewsWire
- 3 months ago - Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Purple Biotech Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025 - GlobeNewsWire
- 5 months ago - Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress - GlobeNewsWire